Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227196 · ClinicalTrials.gov registry record · Phase 1
A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 546
- Enrollment target
NCT05227196 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 546 participants.
The verdict
NCT05227196, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 546 participants
- Enrollment target
Study Summary
The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood in two different tablet versions of Semaglutide. The study will consist of 3 groups and the treatment the participants will get is dependent on the group the participants will be enrolled in. The participants in group 1 will receive treatment for 22 weeks, group 2 for 21 weeks and group 3 for 20 weeks. The study will last up to 29 to 31 weeks for each participant. This includes a screening period (up to 4 weeks), a dose escalation period (up to 2 weeks), a treatment period (20 weeks) and a follow-up period (5 weeks after the last dose).
Interventions
- DRUG Semaglutide D Dose 1
- DRUG Semaglutide D Dose 2
- DRUG Semaglutide D Dose 3
- DRUG Semaglutide Dose 4
- DRUG Semaglutide Dose 5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 546 participants |
| Start Date | 2022-02-04 |
| Est. Completion | 2023-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05227196
The ClinicalTrials.gov registry entry for NCT05227196 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 546 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Semaglutide D Dose 1 is the first listed.
NCT05227196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05227196 about?
NCT05227196 is a clinical study titled "A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People". The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood in two different tablet versions of Semaglutide. The study will consist of 3 groups and the treatment the participants will get is dependent on the group the participants will be enrolled in. ...
What is the current status of trial NCT05227196?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 546 participants. The study started on 2022-02-04. Estimated completion is 2023-08-08.
What interventions are being tested in trial NCT05227196?
The interventions under investigation include: Semaglutide D Dose 1 (DRUG), Semaglutide D Dose 2 (DRUG), Semaglutide D Dose 3 (DRUG), Semaglutide Dose 4 (DRUG), Semaglutide Dose 5 (DRUG).
Who is sponsoring clinical trial NCT05227196?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.